|
1
|
Gupta K, Miller JD, Li JZ, Russell MW and
Charbonneau C: Epidemiologic and socioeconomic burden of metastatic
renal cell carcinoma (mRCC): A literature review. Cancer Treat Rev.
34:193–205. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wei C, Wu S, Li X, Wang Y, Ren R, Lai Y
and Ye J: High expression of FER tyrosine kinase predicts poor
prognosis in clear cell renal cell carcinoma. Oncol Lett.
5:473–478. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bouyssou JM, Manier S, Huynh D, Issa S,
Roccaro AM and Ghobrial IM: Regulation of microRNAs in cancer
metastasis. Biochim Biophys Acta. 1845:255–265. 2014.PubMed/NCBI
|
|
4
|
Schmidt U and Begley CG: Cancer diagnosis
and microarrays. Int J Biochem Cell Biol. 35:119–124. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yu X, Zhang X, Bi T, Ding Y, Zhao J, Wang
C, Jia T, Han D, Guo G, Wang B, et al: MiRNA expression signature
for potentially predicting the prognosis of ovarian serous
carcinoma. Tumour Biol. 34:3501–3508. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Walter BA, Valera VA, Pinto PA and Merino
MJ: Comprehensive microRNA profiling of prostate cancer. J Cancer.
4:350–357. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Miao J, Wu S, Peng Z, Tania M and Zhang C:
MicroRNAs in osteosarcoma: Diagnostic and therapeutic aspects.
Tumour Biol. 34:2093–2098. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li L and Li W: Epithelial-mesenchymal
transition in human cancer: Comprehensive reprogramming of
metabolism, epigenetics, and differentiation. Pharmacol Ther.
150:33–46. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen H, Xia B, Liu T, Lin M and Lou G:
KIAA0101, a target gene of miR-429, enhances migration and
chemoresistance of epithelial ovarian cancer cells. Cancer Cell
Int. 16:742016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fan JY, Fan YJ, Wang XL, Xie H, Gao HJ,
Zhang Y, Liu M and Tang H: miR-429 is involved in regulation of
NF-κB activity by targeting IKKβ and suppresses oncogenic activity
in cervical cancer cells. FEBS Lett. 591:118–128. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Goeppert B, Ernst C, Baer C, Roessler S,
Renner M, Mehrabi A, Hafezi M, Pathil A, Warth A, Stenzinger A, et
al: Cadherin-6 is a putative tumor suppressor and target of
epigenetically dysregulated miR-429 in cholangiocarcinoma.
Epigenetics. 11:780–790. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xiao P, Liu W and Zhou H: miR-200b
inhibits migration and invasion in non-small cell lung cancer cells
via targeting FSCN1. Mol Med Rep. 14:1835–1840. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sheng N, Zhang L and Yang S: MicroRNA-429
decreases the invasion ability of gastric cancer cell line BGC-823
by downregulating the expression of heparanase. Exp Ther Med.
15:1927–1933. 2018.PubMed/NCBI
|
|
14
|
Xue H and Tian GY: MiR-429 regulates the
metastasis and EMT of HCC cells through targeting RAB23. Arch
Biochem Biophys. 637:48–55. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wu D, Niu X, Pan H, Zhou Y, Zhang Z, Qu P
and Zhou J: Tumor-suppressing effects of microRNA-429 in human
renal cell carcinoma via the downregulation of Sp1. Oncol Lett.
12:2906–2911. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen D, Li Y, Li Y, Jin L, Su Z, Yu Z,
Yang S, Mao X and Lai Y: Tumor suppressive microRNA-429 regulates
cellular function by targeting VEGF in clear cell renal cell
carcinoma. Mol Med Rep. 13:1361–1366. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta c(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu K, Liu S, Zhang W, Jia B, Tan L, Jin Z
and Liu Y: miR-494 promotes cell proliferation, migration and
invasion, and increased sorafenib resistance in hepatocellular
carcinoma by targeting PTEN. Oncol Rep. 34:1003–1010. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Meng W, Tai Y, Zhao H, Fu B, Zhang T, Liu
W, Li H, Yang Y, Zhang Q, Feng Y, et al: Downregulation of
miR-33a-5p in hepatocellular carcinoma: A possible mechanism for
chemotherapy resistance. Med Sci Monit. 23:1295–1304. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Qin CZ, Lou XY, Lv QL, Cheng L, Wu NY, Hu
L and Zhou HH: MicroRNA-184 acts as a potential diagnostic and
prognostic marker in epithelial ovarian cancer and regulates cell
proliferation, apoptosis and inflammation. Pharmazie. 70:668–673.
2015.PubMed/NCBI
|
|
21
|
Guo Y, Pang Y, Gao X, Zhao M, Zhang X,
Zhang H, Xuan B and Wang Y: MicroRNA-137 chemosensitizes colon
cancer cells to the chemotherapeutic drug oxaliplatin (OXA) by
targeting YBX1. Cancer Biomark. 18:1–9. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chan SH and Wang LH: Regulation of cancer
metastasis by microRNAs. J Biomed Sci. 22:92015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Machackova T, Mlcochova H, Stanik M,
Dolezel J, Fedorko M, Pacik D, Poprach A, Svoboda M and Slaby O:
MiR-429 is linked to metastasis and poor prognosis in renal cell
carcinoma by affecting epithelial-mesenchymal transition. Tumour
Biol. 37:14653–14658. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yu G, Jia B, Cheng Y, Zhou L, Qian B, Liu
Z and Wang Y: MicroRNA-429 sensitizes pancreatic cancer cells to
gemcitabine through regulation of PDCD4. Am J Transl Res.
9:5048–5055. 2017.PubMed/NCBI
|
|
25
|
Tang J, Li L, Huang W, Sui C, Yang Y, Lin
X, Hou G, Chen X, Fu J, Yuan S, et al: MiR-429 increases the
metastatic capability of HCC via regulating classic Wnt pathway
rather than epithelial-mesenchymal transition. Cancer Lett.
364:33–43. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ouyang Y, Gao P, Zhu B, Chen X, Lin F,
Wang X, Wei J and Zhang H: Downregulation of microRNA-429 inhibits
cell proliferation by targeting p27Kip1 in human prostate cancer
cells. Mol Med Rep. 11:1435–1441. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sun T, Wang C, Xing J and Wu D: miR-429
modulates the expression of c-myc in human gastric carcinoma cells.
Eur J Cancer. 47:2552–2559. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bhaskar PT and Hay N: The two TORCs and
Akt. Dev Cell. 12:487–502. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Engelman JA: Targeting PI3K signalling in
cancer: Opportunities, challenges and limitations. Nat Rev Cancer.
9:550–562. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tang H, Massi D, Hemmings BA, Mandalà M,
Hu Z, Wicki A and Xue G: AKT-ions with a TWIST between EMT and MET.
Oncotarget. 7:62767–62777. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xu N, Lao Y, Zhang Y and Gillespie DA:
Akt: A double-edged sword in cell proliferation and genome
stability. J Oncol. 2012:9517242012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Manning BD and Cantley LC: AKT/PKB
signaling: Navigating downstream. Cell. 129:1261–1274. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chin YR and Toker A: The actin-bundling
protein palladin is an Akt1-specific substrate that regulates
breast cancer cell migration. Mol Cell. 38:333–344. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu H, Radisky DC, Nelson CM, Zhang H,
Fata JE, Roth RA and Bissell MJ: Mechanism of Aktl inhibition of
breast cancer cell invasion reveals a protumorigenic role for TSC2.
Proc Natl Acad Sci USA. 103:4134–4139. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hutchinson JN, Jin J, Cardiff RD, Woodgett
JR and Muller WJ: Activation of Akt-1 (PKB-alpha) can accelerate
ErbB-2-mediated mammary tumorigenesis but suppresses tumor
invasion. Cancer Res. 64:3171–3178. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Maroulakou IG, Oemler W, Naber SP and
Tsichlis PN: Akt1 ablation inhibits, whereas Akt2 ablation
accelerates, the development of mammary adenocarcinomas in mouse
mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T
transgenic mice. Cancer Res. 67:167–177. 2007. View Article : Google Scholar : PubMed/NCBI
|
